Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A10AB05

Fiasp(insulin aspart)

Diabetes Mellitus

Marketing Authorisation Holder: Novo Nordisk A/S

EMA Authorisation: 09/01/2017

INN: insulin aspart

Indication

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Fiasp — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.